US Patent Issued to Iovance Biotherapeutics on Feb. 17 for "Treatment of NSCLC patients with tumor infiltrating lymphocyte therapies" (California Inventors)

ALEXANDRIA, Va., Feb. 17 -- United States Patent no. 12,553,029, issued on Feb. 17, was assigned to Iovance Biotherapeutics Inc. (San Carlos, Calif.).

"Treatment of NSCLC patients with tumor infiltrating lymphocyte therapies" was invented by Maria Fardis (San Carlos, Calif.) and Friedrich-Reinhard Graf Finck Von Finckenstein (San Carlos, Calif.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention provides improved and/or shortened processes and methods for preparing TILs in order to prepare therapeutic populations of TILs with increased therapeutic efficacy for the treatment of non-small cell lung carcinoma (NSCLC), wherein the NSCLC is refractory to treatment with an anti-PD-1 antibody and/o...